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IMMUNOINTERVENTION 
Drug Development and Testing in Relation to Cell Migration 
and Chimerism 
T.E. Starzl, N. Murase, A.J. Demetris, R. Giorda, L. Valdivia, and M. Trucco 
WE will focus first on the meaning of the graft accep-tance that is the transplanter's main reason for 
immunosuppressive drug development, and second on 
how to achieve graft acceptance after xenotransplantation. 
CELL MIGRATION AND CHIMERISM 
Graft acceptance, at least as we now see it, is a process 
that begins within a few minutes after the revascularization 
of any whole organ with a brisk two-way cell traffic in 
which dendritic and lymphoid cells from the recipient and 
those from the graft are exchanged with consequent graft 
and patient chimerism l - J (Fig 1), providing there is effec-
tive immunosuppression. 
Part of the evidence for this concept was obtained by 
studying liver recipients who were alive I (W3 to nearly 23 
years posttransplantation (Table I). Six of these 43 survi-
vors stopped their medication 1 to 11 years after transplan-
tation and have remained drug free for 5 to 13 years. The 
lymphocytes of all these treated or untreated patients 
Fig 1. Cell migration and repopulation after liver transplantation. 
Table 1. Liver Transplantation January 1970 to January 1982 
Total 206 
Surviving 
0If medication 
.Stopped 1 to 11 years postoperatively; 011 drugs 5 to 13 years. 
43 (21%) 
6· 
reacted vigorously to the lymphocytes of third-party do-
nors. We believe that they are tolerant. 
This spring we performed multiple biopsies on six of the 
drug-free patients and on 16 more still under therapy 
looking for evidence of chimerism with HLA markers or 
with sex karyotyping in a subgroup of nine women who 
received male livers (Table 2). Chimerism was detected 
with immunostaining or with polymerase chain reaction 
(PeR) in every case. Biopsy samples were taken of the 
liver, skin. and a convenient lymph node; also, blood was 
examined via PCR. In situ hybridization by Jake Demetris 
using y probes identified the hepatocytes. ducts. and 
endothelial cells as male (bright spots) in the female 
recipients. Male cells in these women also were found in 
the lymph nodes and skin. In the other patients who had 
donors of the same sex, donor cells have been demon-
strated by peR or immunostaining in the intestine. heart, 
bone marrow, blood. or even aorta. The same process 
occurs with the successful transplantation of all other 
kinds of whole organs. including the kidney, although in 
smaller numbers. 
Cell migration is the secret of graft acceptance and the 
explanation for two phenomena described nearly 30 years 
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Table 2. Uver Transplantation: Studies of Chimerism (of 43 
After 10'h to 21 Years) 
Total studied 
Positive chimerism 
Male to female chimerism 
'Immunocytochemistry. PCR. 
tin situ hybridIZation. peR. 
22' 
All studied 
gl9t 
ago: the reversal of kidney rejection by steroids and the 
subsequent ability to reduce the intensity of immunosup-
pression (referred to as tolerance).4 Why this happened 
was a mystery in 1963. In retrospect. the solution to the 
mystery was there all along in exhaustive skin test studies 
on these early Colorado recipients and their donors. Sev-
enty-seven percent of the skin reactions that were positive 
in the donor but not the recipient crossed over to the 
previously negative recipient. along with the transplanted 
kidney. When this did not occur (in the other 23%). it 
meant that the kidney transplant had failed. Our immunol-
ogists. Kirkpatrick and Wilson. speculated (correctly) that 
the migration of the skin tests was "caused by adoptive 
transfer of donor cellular immunity by leukocytes in the 
renal graft vasculature and hilar lymphoid tissue ... 5 
Thus. in retrospect the observations of rejection reversal 
and what was called tolerance were reflections of cell 
migration and repopulation.1.2 Without understanding 
why. the observations led to the empiric therapeutic 
dogma upon which our specialty of whole-organ transplan-
tation is based, and with which new drugs are tested 
clinically (Table 3). The dogma calls for daily baseline 
treatment (in these early days with azathioprine) plus 
intervention with the highly dose-maneuverable adrenal 
cortical steroids (or later antilymphoid agents) to whatever 
level is required to maintain stable graft function. This 
creates a trial and potential error situation for every patient 
as drugs are weaned. Although the new drugs that have 
been added through the years have been increasingly 
potent. they can be viewed as traffic directors-allowing 
cell movement (Fig 1) but preventing the immune destruc-
tion that is the natural purpose of the traffic. It does not 
matter exactly how the immune reaction is disrupted. only 
that this be achieved without killing all of the migratory 
cells. The emasculated but living cells that normally cause 
graft immunogenicity and rejection become instead the 
Table 3. Central Therapeutic Dogma 
Baseline therapy with one or two drugs: 
Azathioprine 
Cyclophosphamide 
Cyclosporine 
Cyclosporine + azathioprine 
FK506 
FK 506 + azathioprine 
Secondary adjustments with steroids or antilymphoid agents 
Case-to-case trial (and potential error) of weaning 
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missionaries subserving chimerism, graft acceptance, and 
ultimately tolerance. 
Disruption of the function of the lymphocyte can be at 
the level of antigen processing (claimed at one time for 
deoxyspergualin). at an early stage in T-cell activation as 
occurs with cyclosporine and FK 506. or distal to this with 
rapamycin. which does not inhibit the secretion of cyto-
kines including interleukin-2 but blocks their action. The 
so-called antiproliferative drugs (of which azathioprine 
was the prototype) work even more distally. 
XENOTRANSPLANT ATION 
Ironically, drugs of this latter class that have been in our 
hands for more than 30 years hold the key that can unlock 
the door to xenotransplantation.6 These antimetabolite 
drugs block enzymes required for the synthesis of ribonu-
c1eotides. Consequently. they inhibit the DNA synthesis 
without which the final step of clonal lymphocyte expan-
sion cannot proceed normally. All of these agents affect 
both T and B lymphocytes. but with some specificity. 
Azathioprine is more T cell directed and cyclophospha-
mide has a greater B-cell effect. 
Although the duality of humoral and cellular mecha-
nisms of xenograft rejection has been common knowledge, 
the antibody component has been refractory to treatment. 
For example. a hamster organ is confronted in the rat by a 
moderate titer (I: 16 to I :32) of preformed heterospecific 
cytotoxic antibodies and subsequently by a rapidly gath-
ering antibody storm that destroys abdominally placed 
cardiac grafts within 3 days in untreated recipients, before 
there is a trace histopathologically of immunocyte infIltra-
tion. By itself, FK 506. which prevents T-cell activation 
and cytokine secretion, could in doses of 2 mg/kgld pro-
long survival by only I day (Table 4). Monotherapy with 
either of two experimental antiproliferative drugs that 
suppress purine (RS 61443) or pyrimidine (Brequinar) 
synthesis tripled or quadrupled survival (Table 4) but did 
not permit consistent chronic survival. However, when 
either of these two antimetabolite drugs or when the 
conventional anticancer drug cyclophosphamide was 
added to FK 506 for the first 2 postoperative weeks. 
extended survival using continued FK 506 alone became 
routinely possible. It was particularly noteworthy that a 
single large dose of cyclophosphamide to days before 
transplantation permitted 100% success with daily FK 506 
(Table 4). 
A complete report of these studies has been published 
elsewhere.6 The conclusion was that prevention or mitiga-
tion of heterospecific antibody rejection by interdiction of 
the B cell-proliferative response with a variety of antime-
tabolite drugs (including some not shown in Table 4) for a 
surprisingly short period after transplantation or even 
beforehand is the essential first step to successful xe-
notransplantation. and unmasks the potential of continu-
ous therapy with T cell-directed immunosuppressants 
such as FK 506. Such combination therapy should be 
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Table 4. Graft Survival 
Grall 
Type 
Heart 
Liver 
Group 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
Treatment" n 
None 6 
FK 506 6 
RS-61443 4 
Brequinar 6 
Cyclophosphamide 5 
Cyclophosphamide 5 
None 8 
FK506 10 
RS-61443 5 
Brequinar 7 
Cyclophosphamide 5 
Cyclophosphamide 5 
Without FK 506 With FK506 
Survival Survival 
>30 days n >30 days 
0 
0 
0 6 5 
1 5 5 
0 5 5 
0 5 5 
0 
5 
0 10 9 
1 7 6 
0 10 9 
0 15 12 
Animals alive at 30 days survived as long as FK 506 was continued for 100 days. no matter what the adjuvant induction drug. 
"Daily dose (mglkg): FK 506. R5-61443. Brequinar. cydophosphamide. 2.0 x 6. 1.0 x 25 (heart) or 1.0 x 30 (liver). and 0.5 on ahemate day thereafter; 20.0 x 15 
(14) starting day before transplant (heart) or day of transplant (liver); 4.0 x 3 and 3.0 x 12 starting day before transplant (heart) or 3.0 x 14 starting day of transplant 
(liver); 7.5 x 15 (14) starting day before transplant (heart) or day of transplant (liver). except groups 6 and 12. who received one dose of 80 mg 10 days preoperatively. 
clinically applicable as long as the humoral antibodies do 
not act so rapidly that they cause hyperacute rejection in a 
matter of a few minutes or hours. This condition has been 
demonstrated empirically with baboon to human kidney7 
and heartS xenotransplantation. 
The effectiveness of cyclophosphamide in these drug 
cocktails was extremely encouraging because cyclophos-
phamide had a firmly established track record for clinical 
allotransplantation (kidney. liver. or heart) in extensive 
trials more than 2 decades ago.9 In those trials in which the 
barrier was cellular (not humoral) immunity. cyclophos-
phamide had about the same potency in drug cocktails as 
azathioprine in head to head comparisons. It could be 
given daily for years. 
After breaking through the antibody barrier. the process 
of xenograft acceptance involves the cell migration and 
consequent systemic chimerism that were recently delin-
eated for allografts. I- 3 With a monoclonal antibody that 
recognizes LEW rat but not hamster cells, \0 we already 
have shown that rat recipient dendritic and lymphoid cells 
-
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Fig 2. Specific amplification of exon 9 of the HPRT gene. S, 
spleen; mL. mesenteric lymph node; cL. cervical lymph node; T, 
thymus; H. heart. S. skin. Rats 1.17.18,46.198, and 238 received 
hamster livers 104 to 141 days previously; rats 19. 24. and 31 
received hearts 111 to 135 days earlier. 
are incorporated into hamster heart or liver xenografts 
examined 3 to 100 days after transplantation. \0 The dis-
placed cells leaving these organs could be detected with 
polyclonal antihamster antisera (unpublished observa-
tions) and confirmed with PCR techniques (Fig 2). 
For the molecular examination of the rat tissues, 1 p.g of 
genomic DNA extracted from each tissue was PCR ampli-
fied for 30 cycles with hamster-specific oligonucleotides. 
One fifth of the volume of each reaction was size separated 
on agarose gel. transferred onto a nylon membrane (Hy-
bond-N +, Amersham, Arlington Heights. Ill), and probed 
with a hamster hypoxantine phosphoribosyltransferase 
(HPRT) exon 9 probe. 11.12 The transplanted organs were 
also analyzed. but their amplifications were not included in 
the experiment shown in Fig 2. in order to allow a clear 
visualization of the fainter signals from the tissues of the 
recipients. Genomic DNAs extracted from hamster and rat 
spleen were amplified as positive and negative controls. 
respectively. 
The chimerism was most obvious and frequent in the 
spleen and/or heart of the recipients. being unequivocal 
after liver transplantation and of low level if present at aU 
after heart transplantation. These findings mean that suc-
cessful clinical xenotransplantation must be visualized 
along the same lines of donor-recipient cellular intimacy as 
I described at the outset to be the fundamental means of 
allograft acceptance. It also means that this is an achiev-
able objective with drugs currently available. The experi-
mental background that I have described was the justifi-
cation for the baboon-ta-human liver transplant that took 
place in Pittsburgh in June 1992. 
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